Silo Pharma (NASDAQ: SILO) received a Notice of Allowance from the U.S. Patent and Trademark Office for a key patent supporting its lead asset, SPC- ...
Researchers have uncovered how neurotransmitters in the brain respond to the emotional content of language, shedding light on the intersection of emotion, cognition, and communication.
The patent, when formally approved, will reinforce protection for Silo’s lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent includes newly added ...